

CEO Remuneration Update

Sydney, 27 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today advises of changes to the remuneration package for the Company’s Chief Executive Officer, Mr. James Bonnar.

FY2023 Fixed Annual Remuneration

Mr. Bonnar is presently on a fixed annual remuneration of \$301,125, inclusive of superannuation contributions, subject to annual review by the Company.

The Board, taking into consideration his performance and other external factors such as CPI movements over the past year, has increased Mr. Bonnar’s fixed annual remuneration for the remainder of FY2023, effective 26 October 2022, by 10% to \$331,238, inclusive of superannuation contributions.

Commenting on the changes, Nyrada Chairman, Mr. John Moore said: “James’ performance during FY2022 in overseeing the Company’s drug development programs during a globally challenging economic period, while maintaining strict discipline in expenditure has been exceptional.

“The Board and I are pleased to see the achievements delivered through James’ leadership this year and look forward to him continuing to drive the Company’s progress over the coming financial year and beyond,” Mr Moore added.

- ENDS-

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize, Investor Relations Manager
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.